Dow Jumps More Than 200 Points; Samsung Sees This Much Surge In Quarterly Revenue
U.S. stocks traded higher midway through trading, with the Dow Jones jumping more than 200 points following the release of data on initial jobless claims.
The Daily Biotech Pulse: Merck’s Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours:
Jefferies Downgrades CytomX Therapeutics to Hold, Lowers Price Target to $2
Jefferies analyst Roger Song downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Hold and lowers the price target from $12 to $2.
BTIG Maintains Buy on CytomX Therapeutics, Lowers Price Target to $8
BTIG analyst Kaveri Pohlman maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $16 to $8.
Why Is GameStop Surging By Around 10%? 22 Stocks Moving In Thursday’s Pre-Market Session
Gainers
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 39.6% to $0.2471 in pre-market trading after declining over 8% on Wednesday. Allena Pharmaceuticals recently announced rescheduling of special meeting to approve reverse stock split.
Mizuho Downgrades CytomX Therapeutics to Neutral, Lowers Price Target to $4
Mizuho analyst Mara Goldstein downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Neutral and lowers the price target from $16 to $4.
BMO Capital Initiates Coverage On CytomX Therapeutics with Outperform Rating, Announces Price Target of $9
BMO Capital analyst Etzer Darout initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a Outperform rating and announces Price Target of $9.